New drug shows promise for tough liver cases
NCT ID NCT06144086
First seen May 03, 2026 · Last updated May 07, 2026 · Updated 2 times
Summary
This small study tested a drug called foscenvivint in 5 adults with liver cirrhosis (scarring) caused by HIV and hepatitis C co-infection, who also have hemophilia. The goal was to see if the drug could improve liver function over 24 weeks. The study is complete, but results are not yet reported.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hokkaido University Hospital
Sapporo, Hokkaido, 060-8648, Japan
-
National Hospital Organization Osaka National Hospital
Osaka, Osaka, 540-0006, Japan
-
Tokyo Metropolitan Komagome Hospital
Bunkyo-Ku, Tokyo, 113-8677, Japan
Conditions
Explore the condition pages connected to this study.